Proefschrift Universiteit van Amsterdam. / Met bibliogr., lit. opg. - Met samenvatting in het Nederlands.

Proefschrift Universiteit van Amsterdam. / Met lit. opg. - Met samenvatting in het Nederlands.

Proefschrift Universiteit van Amsterdam. / Met samenvatting in het Nederlands.

Proefschrift Maastricht. / Auteursnaam op omslag: Chris Reutelingsperger. Lit.opg. - Samenvatting in het Nederlands.

Proefschrift Maastricht. / Met lit. opg. - Met samenvatting in het Spaans en Nederlands.

Proefschrift Maastricht. / Met lit. opg. - Met samenvatting in het Nederlands.

Proefschrift Universiteit Maastricht. / Met lit. opg. - Met een samenvatting in het Nederlands.

Bakgrund: I Sverige var det år 2013, 200 000 personer som behandlades med det blodförtunnande läkemedlet Waran. Forskning på hur en person som behandlas med Waran upplever sin behandling kan bidra till en ökad förståelse kring detta bland hälso- och sjukvårdspersonal. Studien grundar sig på Dahlbergs livsvärldsteori vilken beskriver vårdandet med fokus på personens tankar, upplevelser och hur hälso- och sjukvårdspersonal kan vårda utifrån dessa begrepp. Syfte: Att beskriva upplevelser av att behandlas med Waran Metod: En kvalitativ, deskriptiv intervjustudie. Fem intervjuer genomfördes, vilka baserades på ett frågeformulär med öppna frågor. Analysmetoden består av en manifest analys, som bygger på en kvalitativ innehållsanalys. Resultat: Upplevelser av att behandlas med Waran är individuellt och beror på flertalet olika faktorer i en persons liv. En positiv känsla angående Waran samt en tacksamhet att få ett bättre liv tack vare Waran och slippa oro sig för sjukdomens verkning på kroppen framkom tydligt under intervjuerna. Det fanns dock en oro för de biverkningar som Waran har och detta kom att påverka deltagarna olika. Slutsats: Waranbehandling bidrog till både negativa och positiva upplevelser. Dock med en övervägande gynnsam inställning till Waranbehandling. / Background: In the year of 2013 there were 200 000 persons in Sweden that were under treatment with the blood-thinning drug Warfarin. Studies that describe how people feel and experience their treatment with Warfarin can result in a greater understanding among health-care workers. Dahlberg’s lifeworld theory was used in the study. The theory has focus on people’s feelings, thoughts and experiences. Purpose: Describing the experience of being under treatment with Warfarin. Methods: A qualitative descriptive interview study. Five interviews where completed and the interviews were based on a questionnaire. The majority of the questions were open questions. The data were analysed with a qualitative content analysis with a manifested analysis. Results: Experience of being treated with Warfarin where very individual and depended on many different factors in a person’s life. A positivity and thankfulness to Warfarin appeared during the interviews. There was a concern about side effects from Warfarin, but how this affected the persons that were treated with Warfarin was different between the participants.  Conclusion: Warfarin treatment contributed both positive and negative experiences. The majority of experiences were positively.

Background: Covid-19 is a serious infectious disease that was first discovered in China in 2019. The disease spread very quickly, infecting over 40 million globally and leading to more than a million deaths. The damage caused by the corona infection led to severe thromboembolic conditions that led to death. Therefore, anticoagulants were used in connection with corona to prevent the thromboembolic conditions. But has the use of anticoagulants in covid-19 patients really affected mortality?    Aim: To make a systematic review that explores whether anticoagulant use among COVID-19 patients affect mortality.    Methods: A systematic search was conducted September in 2022 of published studies on PubMed associated with mortality and use of anticoagulants in covid-19 patients. The articles reviewed were selected based on defined PICO and inclusion and exclusion criteria. Types of studies reviewed were cohort and case-control studies.    Results & conclusions:   A total of 20 different studies were studied and based on them it is concluded that anticoagulant treatment associated with lower mortality in severely ill covid-19 patients has been demonstrated. However, bleeding risk was observed in other covid-19 patients due to use of anticoagulants.